LSTA

0.86175.31%
DJ

David J. Mazzo

CEO & Director

Dr. David J. Mazzo, also known as Dave, B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D., has been the Chief Executive Officer of Lisata Therapeutics, Inc. (formerly known as Caladrius Biosciences, Inc.) (formerly Neostem, Inc.) since January 5, 2015 and served as its President since June 2023 until September 17, 2026. Dr. Mazzo served as Independent Non Executive Chairman at Visioneering Technologies, Inc. since February 28, 2020 until February 29, 2024. He served as Lead Independent Director at Seneca Biopharma, Inc. (formerly known as Neuralstem, Inc.) since 2019. Dr. Mazzo is Independent Director at Feldan Bio Inc. (Feldan Therapeutics) since February 2021 and is its Chairman since October 2023. He also served as President at Lisata Therapeutics, Inc. since March 29, 2017 until September 15, 2022. He served as Director of Seneca at Palisade Bio, Inc. Dr. Mazzo is a Director at Seneca Biopharma Inc. (formerly known as Neuralstem, Inc.) since June 2019. Dr. Mazzo served as the President and Chief Executive Officer of Chugai U.S.A., Inc. He served as the Chief Executive Officer of Regado Biosciences, Inc. from August 2008 to October 10, 2014. He served as the President at Regado Biosciences, Inc. since August 2008. He served as the President, Chief Executive Officer & Director of Chugai Pharma USA LLC, the U.S. subsidiary of Chugai Pharmaceutical Ltd. of Japan, since April 2003 until 2007. He served as the President and Chief Executive Officer of AEterna Zentaris Inc. from April 9, 2007 to April 2008. Prior to Chugai, Dr. Mazzo served in management positions in several international pharmaceutical companies, served as Senior Vice President of Global Development Operations at the Schering-Plough Research Institute and as Senior Vice President and Global Head Pharmaceutical Development at Hoechst Marion Roussel. He is a Pharmaceutical Executive and Strategic Leader with broad technical and managerial experience gained from working in a variety of multicultural and multilingual environments in the USA, Canada, Europe and Asia. He has in the pharmaceutical industry and is recognized for his leadership and strong strategic, scientific and regulatory expertise. Dr. Mazzo has also held senior management and executive positions in research and development and was a director of the Essex Chimie European subsidiary at Schering-Plough Corporation. He has served on the board since April 2019. He has broad experience working in a variety of multi-cultural environments in the USA, Europe and Asia where he amassed a track record of successful global product development, registration and launch. He has occupied positions of increasing responsibility with Merck, Baxter, Rhone-Poulenc Rorer, Hoechst AG Marion Roussel and Schering-Plough, where he was involved with the launch of Clarinex (TM), Nasonex(TM), Asmanex Twisthaler(TM), PEG-Intron(TM), PEG-Intron Redipen(TM) and Zetia(TM). Through his multiple assignments and many accomplishments, he has acquired a thorough understanding of the drug development process from Discovery to Manufacturing and Launch. In his previous position as the Senior Vice President of Development Operations for the Schering-Plough Research Institute, he led an organization of approximately 1,100 employees spanning three countries. Dr. Mazzo served as Non-Executive Chairman of EyePoint Pharmaceuticals, Inc. since January 24, 2007 until September 10, 2018 and served as its Director since July 25, 2005 until June 23, 2020. He has been a Director of Lisata Therapeutics, Inc. (formerly known as Caladrius Biosciences, Inc.) since January 5, 2015. He served as a Director of Regado Biosciences, Inc. from August 2008 to October 10, 2014. He served as a Director of AEterna Zentaris Inc. from August 14, 2007 to April 2008. He served as a Director of Avanir Pharmaceuticals, Inc. from July 25, 2005 to January 13, 2015. Dr. Mazzo holds Bachelor of Arts degree in the Honors Program (Interdisciplinary Humanities) and a Bachelor of Science degree in Chemistry from Villanova University. In addition, Dr. Mazzo received his Master of Science degree in Chemistry and his Ph.D. Degree in Analytical Chemistry from the University of Massachusetts, Amherst. He was also a research fellow at the Ecole Polytechnique Federale de Lausanne, Switzerland.

Positions